Patents Assigned to ONO Pharmaceutical Co., Ltd.
-
Patent number: 9763943Abstract: The present invention provides a drug containing a compound having Trk-inhibiting activity as an active ingredient in prophylaxis and/or therapy for Trk-related diseases such as pain, pruritus, lower urinary tract dysfunction, asthma, allergic rhinitis, inflammatory bowel disease or Chagas disease. A compound represented by the general formula (I), wherein all symbols represent the same meanings as described in the specification, a salt thereof, an N-oxide thereof, a solvate thereof or a prodrug thereof is useful as a drug component having Trk-inhibiting activity in prophylaxis and/or therapy of diseases such as pain, pruritus, lower urinary tract dysfunction, asthma, allergic rhinitis, inflammatory bowel disease or Chagas disease.Type: GrantFiled: October 12, 2016Date of Patent: September 19, 2017Assignee: ONO PHARMACEUTICAL CO., LTD.Inventors: Jun Takeuchi, Satoshi Itadani, Kazuya Hashimura, Masahiro Ikura, Masato Higashino, Tetsuya Yasuhiro, Takeshi Nagaura
-
Publication number: 20170240527Abstract: In order to provide a prophylactic and/or therapeutic agent for Trk-related diseases, the present invention provides a compound which has a selective Trk-inhibiting activity and persistently inhibits NGF vascular hyper permeability and does not have a drug interaction and in addition thereto, is excellent in solubility and absorbability against free bases. The compound of the present invention has a selective Trk-inhibiting activity and persistently inhibits NGF vascular hyper permeability and does not have a drug interaction and is excellent in solubility and absorbability against free bases, and is therefore useful as a prophylactic and/or therapeutic agent for Trk-related diseases.Type: ApplicationFiled: August 17, 2015Publication date: August 24, 2017Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Jun TAKEUCHI, Satoshi ITADANI, Masahiro IKURA, Masato HIGASHINO, Hideomi KIJIMA, Shizuka ONO, Tetsuya YASUHIRO, Takeshi NAGAURA
-
Patent number: 9732085Abstract: The present invention provides compounds of the general formula (I), their salts and N-oxides, and solvates and prodrugs thereof (wherein the characters are as defined in the description). The compounds of the general formula (I) are inhibitors of Factor XIa, so that they are useful in the prevention of and/or therapy for thromboembolic diseases.Type: GrantFiled: December 20, 2012Date of Patent: August 15, 2017Assignee: ONO PHARMACEUTICAL CO., LTD.Inventors: Steve Courtney, Chris Yarnold, Stuart Flanagan, Gareth Brace, John Barker, Osamu Ichihara, Elise Gadouleau, Anthony Richardson, Takashi Kondo, Akira Imagawa, Shingo Nakatani, Ryo Suzuki, Sho Kouyama
-
Patent number: 9732082Abstract: Compounds represented by general formula (I) (all of the symbols in the formula conform to the definitions in the Description) are compounds that, in addition to having a Btk-selective inhibitory activity, exhibit an excellent metabolic stability and can avoid hepatotoxicity or the like, and as a consequence can provide safe therapeutic agents for diseases in which B cells or mast cells participate.Type: GrantFiled: December 9, 2014Date of Patent: August 15, 2017Assignee: ONO PHARMACEUTICAL CO., LTD.Inventors: Shingo Yamamoto, Toshio Yoshizawa
-
Publication number: 20170217888Abstract: The present invention relates to a compound represented by the general formula (I) (wherein the definition of each group has the same meaning as described in the specification). The compound is useful as preventive and/or therapeutic agent for KCNQ2-5 channel-related diseases.Type: ApplicationFiled: October 23, 2015Publication date: August 3, 2017Applicant: Ono Pharmaceutical Co., LtdInventors: Kentaro YASHIRO, Daisuke WAKAMATSU, Tetsuji SAITO
-
Patent number: 9701749Abstract: Provided is a prophylactic, symptom progress-suppressive, and/or therapeutic agent for an autoimmune disease. The agent lowers the risk of infections and reduces the burden of administration to patients. The prophylactic, symptom progress-suppressive, and/or therapeutic agent includes a PD-1 agonist as an active ingredient and is administered (a) 1 to 10 times within one month from the first administration, (b) in a total PD-1 agonist dose of 20 to 1250 ?g/kg, and (c) without requiring administration for at least 3 months after the last administration.Type: GrantFiled: August 10, 2012Date of Patent: July 11, 2017Assignee: ONO PHARMACEUTICAL CO., LTD.Inventors: Shiro Shibayama, Masamichi Imai
-
Publication number: 20170189386Abstract: An object of the present invention is to provide a drug having the inhibitory activity on ENPP2 which is a different target from that of the existing drug, as a medicament useful in a urinary excretion disorder patient for whom the existing drug has the insufficient effect. The present invention provides a compound represented by the general formula (1): (wherein definition of each group is as defined in the description) having the ENPP2 inhibitory activity, a salt thereof or a solvate thereof or a prodrug thereof, and an agent for preventing or treating urinary excretion disorder and/or improving symptoms thereof, containing them as an active ingredient.Type: ApplicationFiled: March 21, 2017Publication date: July 6, 2017Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Akira OHATA, Shingo NAKATANI, Tetsuya SUGIYAMA, Takashi MORIMOTO
-
Publication number: 20170183359Abstract: Provision of orally-available and low-toxic somatostatin receptor subtype 2 agonist. Since the compound represented by the general formula (I): wherein all symbols represent the same meanings as those described in the description, a salt thereof, an N-oxide thereof, a solvate thereof, or a prodrug thereof is non-peptidic low-molecular compound which has strong somatostatin receptor subtype 2 agonist activity, the compound is orally-available. Additionally, since the compound is low-toxic, the compound is useful for the prevention and/or treatment of the somatostatin related diseases such as acromegaly or gastrointestinal obstruction.Type: ApplicationFiled: March 16, 2017Publication date: June 29, 2017Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Akiharu ISHIDA, Takeshi MATSUSHITA, Tetsuya SEKIGUCHI, Tatsuya KOMAGATA, Takuya NISHIO
-
Patent number: 9682065Abstract: An agent for treating heart failure, which improves left ventricular diastolic function itself without depending on the diuretic effect or vasodilation effect; controls the pathological condition of diastolic functional failure; and prevents the recurrence, and can prevent dyspnea and death from the pathological condition, is provided. By directly acting on a heart, 4-[(2-{(2R)-2-[(1E,3S)-4-(4-fluorophenyl)-3-hydroxy-1-buten-1-yl]-5-oxo-1-pyrrolidinyl}ethyl)thio]butanoic acid improves left ventricular diastolic function, and can effectively treat diastolic functional failure among heart failure types. Accordingly, by present invention, a new agent for treating heart failure that can relieve diastolic functional failure, for which no effective therapeutic method has been established, can be provided.Type: GrantFiled: August 1, 2012Date of Patent: June 20, 2017Assignee: ONO PHARMACEUTICAL CO., LTD.Inventors: Toshiya Kanaji, Kazuhiro Fuchibe, Masaya Takahashi
-
Patent number: 9676719Abstract: An object of the present invention is to provide a compound having strong human S1P2 antagonistic activity in order to develop a useful medicament for therapy of a S1P2-mediated disease such as a disease resulting from vascular constriction, fibrosis and respiratory disease. The compound represented by the general formula (I), wherein all the symbols have the same meanings as described in the specification, has a halogen atom or a haloalkyl group and a phenoxy group at certain substitution sites, and thus has strong human S1P2 antagonistic activity. Therefore, the compound can be a therapeutic agent for a S1P2-mediated disease, such as a disease resulting from vascular constriction, fibrosis and respiratory disease.Type: GrantFiled: March 25, 2014Date of Patent: June 13, 2017Assignee: ONO PHARMACEUTICAL CO., LTD.Inventors: Kensuke Kusumi, Atsushi Naganawa, Kazuhiro Otsuki, Tetsuya Sekiguchi, Koji Shinozaki, Hiroshi Yamamoto, Yasuko Yamamoto
-
Publication number: 20170137412Abstract: The present invention provides compounds of the general formula (I), their salts and N-oxides, and solvates and prodrugs thereof (wherein the substituents are as defined in the description). The compounds of the general formula (I) are inhibitors of factor XIa, and are useful in the prevention of and/or therapy for thromboembolic diseases.Type: ApplicationFiled: January 23, 2017Publication date: May 18, 2017Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Akira IMAGAWA, Takashi KONDO, Taihei NISHIYAMA, Steve COURTNEY, Chris YARNOLD, Osamu ICHIHARA, Stuart FLANAGAN
-
Patent number: 9643940Abstract: A compound that can be a therapeutic agent for underactive bladder which has low risk of side effects and can be administered orally is provided. Furthermore, a crystal which is advantageous in view of the stability, long-term storage, handleability, easiness of the drug preparation or the like as a drug substance of medicaments is provided. Since a salt of 2-[(2-{(1R,5R)-2-oxo-5-[(1E,4S)-7,8,8-trifluoro-4-hydroxy-4-methyl-1,7-octadien-1-yl]cyclopentyl}ethyl)thio]-1,3-thiazole-4-carboxylic acid or a diastereomeric mixture thereof and 4-piperidinemethanol is a chemically very stable crystal, it can be stored for a long time, and is very useful as a drug substance of medicaments.Type: GrantFiled: August 30, 2013Date of Patent: May 9, 2017Assignee: ONO PHARMACEUTICAL CO., LTD.Inventors: Kousuke Tani, Akihiro Kinoshita, Keisuke Hanada, Yoshiyuki Aratani, Takahiro Nekado, Atsushi Shimabukuro
-
Patent number: 9643951Abstract: The present invention provides a somatostatin receptor subtype 2 agonist. A disclosed compound represented by the general formula (I): wherein all symbols have the same definitions as described in the specification; a salt thereof, an N-oxide thereof or a solvate thereof, or a prodrug of the foregoing is a low-molecular compound having strong somatostatin receptor subtype 2 agonistic activity, and thus can be administered in a simple manner, has high stability and has low toxicity. Therefore, the present compound is useful for prophylaxis and/or therapy of somatostatin-related diseases such as acromegaly and gastrointestinal obstruction.Type: GrantFiled: September 29, 2014Date of Patent: May 9, 2017Assignee: ONO PHARMACEUTICAL CO., LTD.Inventors: Akiharu Ishida, Takeshi Matsushita, Tetsuya Sekiguchi, Yasuyuki Okabe, Tatsuya Komagata, Takuya Nishio
-
Publication number: 20170119742Abstract: The present invention relates to a medicament for preventing and/or treating stress diseases, said medicament being characterized in that (1S)-2-acetyl-1-(4-chloro-2-methoxyphenyl)-5-fluoro-1,2,3,9-tetrahydrospiro[?-carboline-4,1?-cyclopropane] is administered at such a specific dose that a brain TSPO occupancy requiring for expressing the pharmacological effects of the medicament can be obtained.Type: ApplicationFiled: June 11, 2015Publication date: May 4, 2017Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Seishi KATSUMATA, Katsukuni MITSUI
-
Patent number: 9636330Abstract: An object of the present invention is to provide a drug having the inhibitory activity on ENPP2 which is a different target from that of the existing drug, as a medicament useful in a urinary excretion disorder patient for whom the existing drug has the insufficient effect. The present invention provides a compound represented by the general formula (I): (wherein definition of each group is as defined in the description) having the ENPP2 inhibitory activity, a salt thereof or a solvate thereof or a prodrug thereof, and an agent for preventing or treating urinary excretion disorder and/or improving symptoms thereof, containing them as an active ingredient.Type: GrantFiled: February 25, 2015Date of Patent: May 2, 2017Assignee: ONO PHARMACEUTICAL CO., LTD.Inventors: Akira Ohata, Shingo Nakatani, Tetsuya Sugiyama, Takashi Morimoto
-
Patent number: 9630976Abstract: Provision of orally-available and low-toxic somatostatin receptor subtype 2 agonist. Since the compound represented by the general formula (I): [wherein all symbols represent the same meanings as those described in the description] a salt thereof, an N-oxide thereof, a solvate thereof, or a prodrug thereof is non-peptidic low-molecular compound which has strong somatostatin receptor subtype 2 agonist activity, the compound is orally-available. Additionally, since the compound is low-toxic, the compound is useful for the prevention and/or treatment of the somatostatin related diseases such as acromegaly or gastrointestinal obstruction.Type: GrantFiled: July 2, 2013Date of Patent: April 25, 2017Assignee: ONO PHARMACEUTICAL CO., LTD.Inventors: Akiharu Ishida, Takeshi Matsushita, Tetsuya Sekiguchi, Tatsuya Komagata, Takuya Nishio
-
Publication number: 20170088542Abstract: A compound represented by general formula (I) has a strong Axl inhibitory activity by introducing a distinctive bicyclic structure in which a saturated carbon ring is fused to a pyridone ring, and can be a therapeutic agent for Axl-related diseases, for example, cancer such as acute myeloid leukemia, melanoma, breast cancer, pancreatic cancer, and glioma, kidney diseases, immune system diseases, and circulatory system diseasesType: ApplicationFiled: December 8, 2016Publication date: March 30, 2017Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Takayuki INUKAI, Jun TAKEUCHI, Tomoko YASUHIRO
-
Publication number: 20170088615Abstract: The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.Type: ApplicationFiled: October 7, 2016Publication date: March 30, 2017Applicants: E.R. SQUIBB & SONS, L.L.C., Ono Pharmaceutical Co., LTD.Inventors: Alan J. KORMAN, Mohan SRINIVASAN, Changyu WANG, Mark J. SELBY, Bingliang CHEN, Josephine M. CARDARELLI, Haichun HUANG
-
Patent number: 9597436Abstract: Provided is an advanced heart failure treatment material, as a myocardial/cardiovascular regeneration device, that self-assembles, which can improve the universality and be used in an emergency by commercialization with no need of cell-culturing (cell-free) by controlling stem cells, and has a high therapeutic effect on the fundamental treatment of intractable cardiovascular diseases, in particular, advanced heart failure, in which not only the saving of lives but also improving the patient's quality of life (QOL) are urgent issues. The advanced heart failure treatment material includes a pharmaceutical agent, an agent holding for the pharmaceutical agent, and a myocardial support device.Type: GrantFiled: September 13, 2013Date of Patent: March 21, 2017Assignees: Osaka University, Nipro Corporation, Ono Pharmaceutical Co., Ltd.Inventors: Yoshiki Sawa, Shigeru Miyagawa, Satsuki Fukushima, Atsuhiro Saito, Yoshiki Sakai, Kazuhisa Matsuda, Takayuki Maruyama
-
Patent number: 9586967Abstract: A compound represented by the general formula (1) has a pyridone ring structure introduced into a pyrrolo pyrimidine skeleton, so that the compound has a strong Axl inhibitory activity. Consequently, the compound can be used as a therapeutic agent for Axl-related diseases including cancers such as acute myeloid leukemia, melanoma, breast cancer, pancreatic cancer, and glioma, kidney diseases, immune system diseases, and circulatory system diseases.Type: GrantFiled: November 6, 2014Date of Patent: March 7, 2017Assignee: ONO PHARMACEUTICAL CO., LTD.Inventors: Takayuki Inukai, Jun Takeuchi, Tomoko Yasuhiro, Mark Allan Wolf, Vijay Dattaram Pawar, Anjan Chakrabarti, Santhosh Kumar Chittimalla